Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lushang Freda Pharmaceutical Co Ltd stock PB Ratio (=1.24) is close to 5-year low of 1.18.
The historical rank and industry rank for Lushang Freda Pharmaceutical Co's PB Ratio or its related term are showing as below:
SHSE:600223'
s PB Ratio Range Over the Past 10 Years
Min: 1.1 Med: 2.04 Max: 5.43
Current: 1.31
During the past 13 years, Lushang Freda Pharmaceutical Co's highest PB Ratio was 5.43. The lowest was 1.10. And the median was 2.04.
SHSE:600223's PB Ratio is ranked worse than 70.36% of 1714
companies
in the Real Estate industry
Industry Median: 0.82
vs SHSE:600223: 1.31
During the past 12 months, Lushang Freda Pharmaceutical Co's average Book Value Per Share Growth Rate was 2.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lushang Freda Pharmaceutical Co was 71.60% per year. The lowest was -30.60% per year. And the median was 6.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lushang Freda Pharmaceutical Co PB Ratio Related Terms
Lushang Freda Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lushang Freda Pharmaceutical Co PB Ratio Competitor Comparison
For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lushang Freda Pharmaceutical Co PB Ratio vs Real Estate Industry
For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lushang Freda Pharmaceutical Co's PB Ratio falls into.
Lushang Freda Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lushang Freda Pharmaceutical Co (SHSE:600223) has a PB Ratio of 1.31 as of Aug. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is 36% below median its historical median of 2.04. Over the past decade, Lushang Freda Pharmaceutical Co's PB Ratio has ranged from 1.10 to 5.43. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #1206 out of 1714 companies in the Real Estate industry, placing it in the top 70.4%.
Is Lushang Freda Pharmaceutical Co's PB Ratio too high?
Lushang Freda Pharmaceutical Co's current PB Ratio of 1.31 is 36% below median its 10-year median of 2.04. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 5.43. The Real Estate industry median PB Ratio is 0.82. Lushang Freda Pharmaceutical Co's value of 1.31 is 59.8% above this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #1206 out of 1714 companies in the Real Estate industry, which is below the industry midpoint. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's PB Ratio compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #1206 out of 1714 companies for PB Ratio. This places Lushang Freda Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 0.82. Lushang Freda Pharmaceutical Co's value of 1.31 is 59.8% above this benchmark. Historically, Lushang Freda Pharmaceutical Co's own PB Ratio has ranged from 1.10 to 5.43 over the past decade. While the company's 10-year median is 2.04 vs. the industry median of 0.82, Lushang Freda Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Real Estate company?
The median PB Ratio among Real Estate companies is 0.82, based on 1,714 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current PB Ratio of 1.31 is 59.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median PB Ratio is 0.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current PB Ratio is 1.31, which is 36% below median its own 10-year median of 2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.56, compared to a current price of ¥5.51 — trading 16% below its estimated fair value. The current PB Ratio is 1.31, which is 36% below median its 10-year median of 2.04 and 59.8% above the Real Estate industry median of 0.82. Lushang Freda Pharmaceutical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current PB Ratio is 1.31 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.51 is trading 16% below its estimated GF Value™ of ¥6.56.
GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600223:
PB Ratio: 1.31 (36% below median its 10-year median of 2.04)
GF Value™: ¥6.56 vs. price of ¥5.51 (16% below fair value)
Industry Position: 59.8% above the Real Estate median (#1206 of 1714)
No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
68GF Score
Get the complete analysis for SHSE:600223
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600223 has been successfully added to your 
